Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults
Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults
复制标题
DOI：
10.1097/inf.0000000000001214
复制
发表时间：
2016-09-01
影响因子：
3.6
通讯作者：
Cressey, Tim R.
中科院分区：
文献类型：
--
作者：
Foca, Marc;Yogev, Ram;Cressey, Tim R.
背景资料：阿匹韦林（RPV）是最近开发的一种每日一次的人类免疫缺陷病毒非核苷逆转录酶抑制剂，目前尚未批准用于儿科患者，但有时用于多次治疗失败的青少年，以简化方案或尽量减少毒性。达芦那韦/利托那韦（DRV/r）每日一次给药也越来越多地用于青少年，并可能改变RPV的药代动力学（PK）。我们在青少年和年轻人中评估了RPV和DRV/r之间的PK相互作用，每天一次。方法：12至18岁的人类免疫缺陷病毒感染受试者
Background: Rilpivirine (RPV), a recently developed, once daily human immunodeficiency virus non-nucleoside reverse transcriptase inhibitor, is not currently approved for pediatric patients, but is sometimes prescribed for adolescents with multiple treatment failures, for regimen simplification or to minimize toxicity. Darunavir/ritonavir (DRV/r) administered once daily is also increasingly used in adolescents and may alter RPV pharmacokinetics (PK). We evaluated the PK interactions between RPV and DRV/r once daily in adolescents and young adults.Methods: Human immunodeficiency virus-infected subjects 12 to